Recent Updates
Recently added Catalysts

Neurogenic Orthostatic Hypotension: one US-listed biotech with a clinical-stage programme

Neurology & PsychiatryUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$887Muniverse median $1.20B
Allocated capital$887M$887M competing
Phase 3 or filed10 mid, 0 early
Pure plays1this indication only
Capital rank157/299crowding rank 169

Neurogenic Orthostatic Hypotension is uncontested. Theravance Biopharma (TBPH) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Ampreloxetine in phase 3.

There is no public comparable to price it against, and TBPH runs clinical programmes in this indication and nothing else, so its $887M market cap is a direct read on what the market thinks this programme is worth.

The one programme here is in late-stage development, but it carries no dated catalyst in the next 12 months.

$887M of allocated capital sits in Neurogenic Orthostatic Hypotension, ranking it 157th of 299 indications by the money committed to it.

Companies developing drugs for Neurogenic Orthostatic Hypotension 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
TBPHTheravance BiopharmaAmpreloxetinePhase 31$887MYes1No dated event

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Neurogenic Orthostatic Hypotension counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Neurogenic Orthostatic Hypotension has one competitor and a median of $887M.

Neurology & Psychiatry

Neurology & Psychiatry holds $120B of the map's capital, 17.9% of the total, spread across 46 indications and 58 companies. 19 of those indications have more than one company competing.

See every Neurology & Psychiatry indication on the map

Related indications in Neurology & Psychiatry

Frontotemporal Dementia1 company · $729M · median $3.6BUncontestedPelizaeus Merzbacher Like Disease1 company · $1.1B · median $9.7BUncontestedMultiple System Atrophy2 companies · $1.1B · median $4.9BConcentrated betEpilepsy1 company · $639M · median $2.6BUncontestedAcute Ischemic Stroke2 companies · $486M · median $1.3BConcentrated betMajor Depressive Episode1 company · $426M · median $1.3BUncontestedPrimary Erythromelalgia1 company · $342M · median $2.4BUncontestedTonic-Clonic Seizures1 company · $1.5B · median $5.8BUncontested

Neurogenic Orthostatic Hypotension pipeline questions

Which biotech companies are developing drugs for Neurogenic Orthostatic Hypotension?

Theravance Biopharma (TBPH, Ampreloxetine, Phase 3). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Neurogenic Orthostatic Hypotension.

How advanced is the Neurogenic Orthostatic Hypotension pipeline?

Of the 1 clinical-stage programme in Neurogenic Orthostatic Hypotension, 1 is in Phase 3 or filed, 0 are in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Neurogenic Orthostatic Hypotension?

No. TBPH is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Neurogenic Orthostatic Hypotension, which is why the indication is classified as uncontested.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map